Double-blind trials were conducted in volunteers to evaluate the efficacy of the prophylactic 3,4-dihydro-1-isoquinolineacetamide hydrochloride (DIQA) treatment against rhinovirus type 24 challenge. Ten men received a 7-day course of DIQA treatment and 11 men received a placebo. The intranasal viral challenge dose was 10 mean tissue culture infective doses. The oral administration of 1 g prechallenge and 2 g a day for 6 consecutive postchallenge days did not prevent the development of colds. Nine drug-treated men and 10 controls developed rhinovirus illness. However, the illnesses of the drug-treated men were mild. Rhinorrhea occurred less frequently and was more mild in the drug-treated group. The challenge virus was recovered from 80% of these subjects in both groups, but almost twice the number of challenge viruses were isolated from the controls than from the drug-treated men. The prophylactic DIQA therapy appears to suppress the cold syndrome and to reduce virus excretion, although its effect is marginal. Additional clinical trials are warranted to confirm the antirhinoviral effect of this drug.
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An antiviral compound, 3, 4-dihydro-1-isoquinolineacetamide hydrochloride (DIQA; Fig. 1 ) has been shown to be prophylactically effective in mice against infections produced by influenza (A/PR/8/34 and A/Japan/305/57), ECHO 9 (Coxsackie A23), herpes simplex, encephalomyocarditis (Columbia SK), St. Louis encephalitis, and West Nile viruses. The drug exhibited prophylactic and therapeutic activity against mumps infection in monkeys and effectively suppressed the development of herpes keratitis in rabbits, but the drug did not exert any effect on these viruses in tissue cultures.
DIQA was active against Coxsackievirus Bi and vaccinia in tissue cultures, but was ineffective in vivo (1) (2) (3) 6) .
Two isoquinoline derivatives (UK 2054 and UK 2371) inhibited the in vitro growth of viruses belonging to the myxovirus and picornavirus groups (4 Virology materials and methods. The materials and procedures for the virus isolation from the nose and for the neutralizing antibody titrations of serum and nasal washing samples have been described elsewhere (9) .
In vitro sensitivity of rhinovirus types 24, 1B, 32, ANTIVIRAL EFFECT OF DIQA 613 and 44 to DIQA was evaluated. The drug concentrations, ranging from 1,000 to 1.95 1sg/ml, were tested against 100 TCID5O of each of the viruses. The reduction of the infectivity titer of the rhinovirus which was cultured with the medium containing 100 1g/ml of DIQA was also studied. The details of this procedure have also been described (9) . In order to determine the direct activity of DIQA on the rhinoviruses, the drug solution and each of the viruses were mixed together to make the drug concentration in the mixture 1,000 AgIml. The mixtures were left at 37 C for 1 h, after which the viruses were titrated in WI-38 cell tube cultures, and the titers were compared to those of controls. WI-38 cell tube cultures were rolled at 35 C during these experiments.
RESULTS
Of the 21 subjects, 10 received DIQA and 11 received a placebo. Age and body weight distributions were comparable in the two groups.
Induced rhinovirus infection. Nine of the 10 DIQA-treated men and 10 of the 11 placebotreated men developed mild to moderately severe colds after the intranasal rhinovirus 24 challenge (Table 1) . One man in each group had a 1-day elevation of body temperature (38.3 C [101 F] for the drug-treated man and 37.7 C [99. 8 F] for the placebo-treated man), hence heir scores were upgraded to 3+.
In the DIQA-treated group, six men developed 1+ to 2+ illness accompanied by seroconversion with one or two type 24 virus isolations between days 1 and 4. In the two men who had a mild cold, no challenge virus was isolated, but an antibody titer rise was demonstrated. One man who developed 2+ illness with fever excreted type 24 virus on days 1 and 2. However, his convalescent titers for the type 24 virus and type 1B virus (concurrent rhinovirus detected in the first study) remained unchanged at <1:2.
One subject (no. 8, H.G.) was asymptomatic throughout the study period, but excreted type 1B virus on day 1 and challenge virus on days 2, 5, and 9. He subsequently developed antibodies for both viruses. Type 1B virus was carried by a placebo subject in the first study, which appears to have been transmitted to this drugtreated man.
In Illness scores. There was no difference between the two groups in the frequency of the illnesses. The frequency of moderately severe illnesses (2+ and 3+) was also not different. However, the total illness (sign plus symptom) scores and total symptom scores were consistently higher in the placebo group on days 2, 3, 4, and 5, although these differences were not statistically significant (Fig. 2) . Some signs and symptoms, i.e., rhinorrhea, nasal stuffiness, headache, cough, and sneezing occurred more frequently in the placebo controls. Rhinorrhea was observed in eight controls and three drugtreated men on day 3 and in six controls and two drug-treated men on day 4 viruses and 4 type 1B viruses for the placebo group and 12 type 24 viruses and 1 type 1B virus for the drug group. Therefore, almost twice the number of type 24 viruses were isolated from the placebo group than from the drug group. On day 3, five placebo-treated men and one drugtreated man excreted type 24 virus. The frequency of the virus isolation from men in both groups on any day during 10 days after the challenge, including day 3, was not significantly different.
Serum and nasal secretory antibody titers.
All but one man in the drug-treated group (90%) and three men in the placebo group (73%) showed serum neutralizing antibody titer increases for the challenge virus ( Table 1 ). The 4-week postchallenge titers were in a range of < 1: 2 to 1:1,024 for both groups. The geometric mean titers for the drug and placebo groups were 1:39 and 1: 19, respectively, which were not significantly different. Eight drug-treated men (80%)-and six placebo controls (55%) developed nasal secretory antibody. The titer ranges were from < 1: 2 to 1: 21 with a geometric mean titer of 1:4.8 for the drug-treated group and from < 1:2 to 1:23 with a geometric mean titer of 1:2.7 for the placebo group.
Concurrent rhinovirus infection. Concurrent rhinovirus type 1B infection was found in the first study. Type 1B virus was isolated from one each of the controls and the drug-treated subjects, both men having serum titer increases for this virus. Type 1B virus was not isolated from the remaining men. Of these, four drugtreated men and one placebo control remained antibody-free and the rest had unchanged serum titers at the 4th week postchallenge (Table 1) .
Side effect of DIQA. No adverse reaction attributable to the ingestion of 2 g a day of DIQA for 7 days was noted. One placebo-treated man developed transient urticarial lesions on his hands and forearms on day 5. The discoloration of urine (orange to red amber) was noted in five men while taking DIQA and in one man who received a placebo. All hematology, blood chemistry, and urinalysis results were within the normal limits.
In vitro activity of DIQA on rhinoviruses. DIQA did not inhibit the growth of all four types of rhinovirus at concentrations up to 1,000 gg/ml. Cytotoxic 
DISCUSSION
The inoculation of 10 TCID5O of rhinovirus type 24 resulted in the development of colds of various severity in 90% of placebo-treated men. Although the challenge dose was small, the incubation period was not extended, and the peak of the illness was on the 3rd postchallenge day. However, the frequency of the virus recovery from each man was low, i.e., nearly one-half of the subjects excreted the virus only once during a 9-day postchallenge period. The antibody response was undetectable in 3 of the 11 placebo controls. These three men excreted the virus one time, and two of them had a mild illness. The viral challenge dose should be minimal to allow the test drug a fair chance to exert its action against the virus. If the dose is exceedingly small, no illness will be produced and should the illness be induced, enough data in the clinical or laboratory parameters, or both, to insure that the illness was caused by the challenge virus will not be attainable. Thus, 10 TCID5O of type 24 virus appears to be the appropriate dose for the investigation of the drug antiviral effect with the number of subjects employed in this study.
DIQA did not inhibit the growth of four types of rhinovirus, including the challenge virus under the conditions of the experiments employed in the present study. The inhibitory activity of an isoquinoline derivative (UK 2054) against rhinovirus was demonstrated in HeLa cell cultures, but not in HEL-218 cell cultures (a semicontinuous line of human embryonic lung fibroblasts similar to WI-38 cells) (7) . Therefore, further studies using HeLa cell cultures or a more sensitive technique, such as the plaquereduction technique, are warranted. Other isoquinoline derivatives (UK 2371 and UK 2054) were shown to have no direct inactivating effect on viral infectivity, but were capable of inhibiting cytopathic effects and multiplication of rhinoviruses. These compounds had different modes of action on myxoviruses, i.e., direct inactivation of viral infectivity and the inability to interfere with the reproductive cycle (4). DIQA had no interferon-inducing action in mice, and its effect on Columbia SK virus appeared to be on a step in the virus-cell interaction between adsorption and replication (6) .
Concurrent rhinovirus type 1B asymptomatic infection was noted in the first trial. The type 1B virus carried by the placebo-treated men was transmitted to only one drug-treated man among the five men in the drug-treated group and the one man in the placebo-treated group who did not have circulating antibody to type 1B virus. DIQA might have prevented the spread of type 1B virus, but because of the small number of subjects, no conclusion can be drawn.
Although the DIQA treatment did not prevent the development of colds, the illness was more mild in the drug-treated group and, in particular, rhinorrhea occurred less frequently and was more mild in this group. The total number of virus isolates was smaller in the drug-treated group. The prophylactic DIQA treatment appears to suppress the cold syndrome and to reduce virus excretion in man, although its effect is marginal. Additional clinical trials are warranted to confirm the antirhinoviral effect of this drug.
